NCT06371534View on ClinicalTrials.gov

A Study Comparing Pharmacokinetic and Safety of QL2109 and DARZALEX FASPRO® in Healthy Adults

PHASE1RecruitingINTERVENTIONAL
Enrollment

228

Participants

Timeline

Start Date

April 12, 2024

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2025

Conditions
Tumor
Interventions
DRUG

QL2109

subcutaneous injection 3-5 min D1 (Day 1, single dose)

DRUG

DARZALEX FASPRO®

subcutaneous injection 3-5 min D1 (Day 1, single dose)

Trial Locations (2)

310006

RECRUITING

The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

NOT_YET_RECRUITING

The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY